444 related articles for article (PubMed ID: 18550240)
1. Quantitative assessment of cumulative carcinogenic risk for multiple genotoxic impurities in a new drug substance.
Bercu JP; Hoffman WP; Lee C; Ness DK
Regul Toxicol Pharmacol; 2008 Aug; 51(3):270-7. PubMed ID: 18550240
[TBL] [Abstract][Full Text] [Related]
2. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity.
Müller L; Mauthe RJ; Riley CM; Andino MM; Antonis DD; Beels C; DeGeorge J; De Knaep AG; Ellison D; Fagerland JA; Frank R; Fritschel B; Galloway S; Harpur E; Humfrey CD; Jacks AS; Jagota N; Mackinnon J; Mohan G; Ness DK; O'Donovan MR; Smith MD; Vudathala G; Yotti L
Regul Toxicol Pharmacol; 2006 Apr; 44(3):198-211. PubMed ID: 16412543
[TBL] [Abstract][Full Text] [Related]
3. Improved in silico prediction of carcinogenic potency (TD50) and the risk specific dose (RSD) adjusted Threshold of Toxicological Concern (TTC) for genotoxic chemicals and pharmaceutical impurities.
Contrera JF
Regul Toxicol Pharmacol; 2011 Feb; 59(1):133-41. PubMed ID: 20933038
[TBL] [Abstract][Full Text] [Related]
4. In silico approaches to predicting cancer potency for risk assessment of genotoxic impurities in drug substances.
Bercu JP; Morton SM; Deahl JT; Gombar VK; Callis CM; van Lier RB
Regul Toxicol Pharmacol; 2010; 57(2-3):300-6. PubMed ID: 20363275
[TBL] [Abstract][Full Text] [Related]
5. Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances.
Humfrey CD
Toxicol Sci; 2007 Nov; 100(1):24-8. PubMed ID: 17656486
[TBL] [Abstract][Full Text] [Related]
6. Overview of genotoxic impurities in pharmaceutical development.
Bercu JP; Dobo KL; Gocke E; McGovern TJ
Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the genotoxic and carcinogenic risks of p-nitrophenol when it is present as an impurity in a drug product.
Eichenbaum G; Johnson M; Kirkland D; O'Neill P; Stellar S; Bielawne J; DeWire R; Areia D; Bryant S; Weiner S; Desai-Krieger D; Guzzie-Peck P; Evans DC; Tonelli A
Regul Toxicol Pharmacol; 2009 Oct; 55(1):33-42. PubMed ID: 19500632
[TBL] [Abstract][Full Text] [Related]
8. Determination of compound-specific acceptable daily intakes for 11 mutagenic carcinogens used in pharmaceutical synthesis.
Ellis P; Kenyon M; Dobo K
Regul Toxicol Pharmacol; 2013 Mar; 65(2):201-13. PubMed ID: 23228434
[TBL] [Abstract][Full Text] [Related]
9. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development.
Dobo KL; Greene N; Cyr MO; Caron S; Ku WW
Regul Toxicol Pharmacol; 2006 Apr; 44(3):282-93. PubMed ID: 16464524
[TBL] [Abstract][Full Text] [Related]
10. Approaches to the risk assessment of genotoxic carcinogens in food: a critical appraisal.
O'Brien J; Renwick AG; Constable A; Dybing E; Müller DJ; Schlatter J; Slob W; Tueting W; van Benthem J; Williams GM; Wolfreys A
Food Chem Toxicol; 2006 Oct; 44(10):1613-35. PubMed ID: 16887251
[TBL] [Abstract][Full Text] [Related]
11. Comparison of carcinogenic and in vivo genotoxic potency estimates.
Sanner T; Dybing E
Basic Clin Pharmacol Toxicol; 2005 Feb; 96(2):131-9. PubMed ID: 15679476
[TBL] [Abstract][Full Text] [Related]
12. Potentially mutagenic impurities: analysis of structural classes and carcinogenic potencies of chemical intermediates in pharmaceutical syntheses supports alternative methods to the default TTC for calculating safe levels of impurities.
Galloway SM; Vijayaraj Reddy M; McGettigan K; Gealy R; Bercu J
Regul Toxicol Pharmacol; 2013 Aug; 66(3):326-35. PubMed ID: 23688841
[TBL] [Abstract][Full Text] [Related]
13. Guidelines for the evaluation of chemicals for carcinogenicity. Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment.
Rep Health Soc Subj (Lond); 1991; 42():1-80. PubMed ID: 1763238
[TBL] [Abstract][Full Text] [Related]
14. Overall impact of the regulatory requirements for genotoxic impurities on the drug development process.
Giordani A; Kobel W; Gally HU
Eur J Pharm Sci; 2011 May; 43(1-2):1-15. PubMed ID: 21420491
[TBL] [Abstract][Full Text] [Related]
15. Guidelines and pharmacopoeial standards for pharmaceutical impurities: overview and critical assessment.
Snodin DJ; McCrossen SD
Regul Toxicol Pharmacol; 2012 Jul; 63(2):298-312. PubMed ID: 22507740
[TBL] [Abstract][Full Text] [Related]
16. A strategy for the risk assessment of human genotoxic metabolites.
Dobo KL; Obach RS; Luffer-Atlas D; Bercu JP
Chem Res Toxicol; 2009 Feb; 22(2):348-56. PubMed ID: 19170655
[TBL] [Abstract][Full Text] [Related]
17. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L; Gocke E; Lavé T; Pfister T
Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
[TBL] [Abstract][Full Text] [Related]
18. Genotoxic and carcinogenic effects of gastrointestinal drugs.
Brambilla G; Mattioli F; Martelli A
Mutagenesis; 2010 Jul; 25(4):315-26. PubMed ID: 20478972
[TBL] [Abstract][Full Text] [Related]
19. A perspective on testing of existing pharmaceutical excipients for genotoxic impurities.
Brusick DJ
Regul Toxicol Pharmacol; 2009 Nov; 55(2):200-4. PubMed ID: 19607870
[TBL] [Abstract][Full Text] [Related]
20. Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling.
Valerio LG; Arvidson KB; Chanderbhan RF; Contrera JF
Toxicol Appl Pharmacol; 2007 Jul; 222(1):1-16. PubMed ID: 17482223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
